Reata to seek FDA approval after positive pivotal data in rare disease

15 October 2019

Shares of Reata Pharmaceuticals (Nasdaq: RETA) rocketed yesterday, after it said it will seek FDA approval for drug candidate omaveloxolone (omav) for the treatment of Friedreich’s ataxia (FA) following Monday’s announcement of positive data from its registrational clinical trial.

The stock rose 5% by close of trading and then leapt a further 34.4% to $135.43 in after-hours trading.

The study met its primary endpoint, with patients experiencing a significant slowing of disease progression after 48-weeks of treatment. This trial is the first to demonstrate a significant improvement in neurological function in patients with FA and could be the first ever FDA approved drug for these patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK